Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Spectrum Pharmaceuticals, Inc.    SPPI

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/13/2017 01/17/2017 01/18/2017 01/19/2017 01/20/2017 Date
4.65(c) 4.55(c) 4.61(c) 4.6(c) 4.595(c) Last
521 490 467 360 282 513 331 954 415 742 Volume
+1.97% -2.15% +1.32% -0.22% -0.11% Change
More quotes
Financials ($)
Sales 2016 139 M
EBIT 2016 -66,1 M
Net income 2016 -74,9 M
Debt 2016 -
Yield 2016 -
Sales 2017 114 M
EBIT 2017 -66,3 M
Net income 2017 -75,2 M
Debt 2017 -
Yield 2017 -
P/E ratio 2016 -
P/E ratio 2017
Capi. / Sales2016 2,67x
Capi. / Sales2017 3,23x
Capitalization 370 M
More Financials
Company
Spectrum Pharmaceuticals, Inc. engages in the acquisition, development, and commercialization of pipeline of late-stage clinical and commercial products.It targets non-Hodgkin's lymphoma, advanced metastatic colorectal cancer, acute lymphoblastic leukemia, and multiple myeloma.It operates through... 
More about the company
Surperformance© ratings of Spectrum Pharmaceuticals,
Trading Rating : Investor Rating :
More Ratings
Latest news on SPECTRUM PHARMACEUTICALS,
01/09 SPECTRUM PHARMACEUTICALS INC : Regulation FD Disclosure, Financial Statements an..
2016 SPECTRUM PHARMACEUTICALS : Research Reports Initiation on Biotech Stocks -- Incy..
2016 SPECTRUM PHARMACEUTICALS : Highlights Promising Preclinical Data Evaluating Pozi..
2016 SPECTRUM PHARMACEUTICALS : U.S. Patents Awarded to Inventors in Nevada (Dec. 7)
2016 SPECTRUM PHARMACEUTICALS : Assigned Patent
2016 SPECTRUM PHARMACEUTICALS : Highlights Survival Advantage in a Case Match Control..
2016 SPECTRUM PHARMACEUTICALS : Highlights Five Abstracts on ROLONTIS™ (eflapeg..
2016 SPECTRUM PHARMACEUTICALS : Highlights Four Abstracts at the 58th Annual Meeting ..
2016 Continuing Challenges Hanmi Pharmaceutical Continues to Challenge for New Glo..
2016 SPECTRUM PHARMACEUTICALS, INC. : Purcell Julie & Lefkowitz LLP Is Investigating ..
More news
Sector news : Biotechnology & Medical Research - NEC
01/13DJNOVARTIS : Supreme Court to Weigh How Soon Firms Can Sell Copycat Biotech Drugs
01/12 Investors in big pharma, biotech look to ride out Trump storm
01/12DJHot Stocks to Watch in the U.S. and Canada
01/10 Regeneron CEO says Amgen not putting patients first in patent dispute
01/09DJCELGENE : Anticipates Slowing Sales Growth for Main Drug Revlimid
More sector news : Biotechnology & Medical Research - NEC
Latest Tweets
01/19Get the latest news and updates for $HCKT $NFBK $BDC $TKR $SPPI automatically.. 
01/11Spectrum Pharmaceuticals downgraded by Zacks Investment Research to sell.  
01/05If $SPPI breaks above 4.75-5 area can explode a lot higher near term #bullish.. 
01/04$SPPI above 4.75+ very bullish #pharma #bullish 
2016Get the latest news and updates for $SPPI $ARII $JCOM $DMND $CAI automaticall.. 
More tweets
Qtime:39
News from SeekingAlpha
2016 FDA rejects Spectrum Pharma's NDA for QAPZOLA
2016 Spectrum Pharma Q3 top line up 17%; net loss narrows
2016 Spectrum Pharmaceuticals beats by $0.23, misses on revenue
2016 After Hours Gainers / Losers
2016 Spectrum Pharmaceuticals beats on revenue
Advertisement
Chart SPECTRUM PHARMACEUTICALS,
Duration : Period :
Spectrum Pharmaceuticals,  Technical Analysis Chart | SPPI | US84763A1088 | 4-Traders
Full-screen chart
Technical analysis trends SPECTRUM PHARMACE...
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Average target price 9,00 $
Spread / Average Target 96%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Rajesh C. Shrotriya Chairman & Chief Executive Officer
Joseph G. Turgeon President & Chief Operating Officer
Kurt A. Gustafson Chief Financial Officer & Executive Vice President
Stuart Mitchell Krassner Independent Non-Employee Director
Anthony E. Maida Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
SPECTRUM PHARMACEUTICA..3.72%370
INCYTE CORPORATION17.21%22 083
QUINTILES IMS HOLDINGS..0.07%18 734
CELLTRION, INC.--.--%10 483
LONZA GROUP AG4.14%9 679
ALKERMES PLC0.72%8 507
More Results